In 1988, the ARCHIVES published the preliminary findings of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP Study).1 Even 16 years later, I vividly recall the tremendous excitement generated by that report, for after more than 20 years of uncertainty, here at last was an effective treatment for one of the major causes of childhood blindness. This issue of the ARCHIVES contains the final results2 from the CRYO-ROP Study, which report the outcomes of those babies who were randomized to treatment in the 1980s and who are now teenagers at 15 years of age. This marks the end of the line for the CRYO-ROP Study so now is the obvious time to glance back to review the impact of this study and see whether the hope to reduce retinopathy of prematurity (ROP) blindness has been realized in the long-term. With reports of outcome at 1, 3.5, 5.5, 10, and 15 years, this study proffers a unique insight into acute-phase ROP, its natural history, response to treatment, and its long-term sequelae of those eyes that were treated and those that were not. The findings of the study are far too numerous to discuss in their entirety, but we have learned, for instance, that African American babies are less likely to develop ROP than white babies3; that the onset, progression,4 and involution5 of acute-phase ROP are all related more closely to postmenstrual age than neonatal events; and that eyes in the acute phase of ROP exhibit a high degree of interocular symmetry.6 A particularly important aspect of the CRYO-ROP Study has been to identify the prognostic value of clinical signs, thus the degree of retinal vascular development,7 the posterior zone of involvement,8 and plus disease8,9 are all very strong predictors of poor outcome. The comments so far are now so ingrained in our understanding that it is difficult to remember that this knowledge has all come from the CRYO-ROP Study.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.